

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	TBA
				Filing Date	May 2, 2006
				First Named Inventor	Paula Fernström
				Art Unit	TBA
Examiner Name	TBA				
Sheet	1	of	1	Attorney Docket Number	1103326-0740

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		US-6,245,818	6-12-2001	Lignell	
		US-6,313,136	11-6-2001	Amin et al.	
		US-6,313,137	11-6-2001	Amin et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 99/55706	11-4-1999	Amin et al.		
		WO 00/17200	3-30-2000	Postius et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		KAMINSKI ET AL., "Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity of Substituted Imidazo[1,2-a] pyridines and Related Analogues", J. Med. Chem, 1989, vol. 32, page 1686-1700.	
		N. VAKIL, "Review Article: New Pharmacological Agents for the Treatment of Gastro-oesophageal Reflux Disease", Aliment. Pharmacol. Ther., 2004, vol. 19, page 1041-1049.	
		SACHS ET AL., "Current Trends in the Treatment of Upper Gastrointestinal Disease", Best Practice & Research Clinical Gastroenterology, 2002, vol. 16, no. 6, page 835-849.	
		WURST ET AL., "Current Status of Acid Pump Antagonists (Reversible PPIs), Yale J. of Biol. and Med., 1996, vol. 69, page 233-243.	
		POPE ET AL., "Reversible Inhibitors of the Gastric (H ⁺ /K ⁺)-ATPase Both Potential Therapeutic Agents and Probes of Pump Function.", Biol. Society Transactions, 1992, vol. 20, page 566-572.	
		WALLMARK ET AL., "Inhibition of Gastric H ⁺ , K ⁺ -ATPase and Acid Secretion by SCH 28080, a Substituted Pyridyl(1,2a)imidazole", J. Biol. Chem, 15 Feb. 1987, page 2077-2084.	
		JOHNSON ET AL., "Esophageal Epithelial Response to Gastroesophageal Reflux. A Quantitative Study", Am. J. Digestive Diseases, 23(6), page 498-509 (1978).	
		DE HAAN ET AL., "Oral Controlled Release Dosage Forms. A Review", Pharmaceutisch Weekblad Scientific Edition, 6, (1984), page 57-67.	
		LANGER AND WISE, eds., "Pharmaceutical Applications of Controlled Release: An Overview of the Past, Present, and Future", in "Medical Application of Controlled Release, vol. II" Boca Raton, FL, (1984) pages 1-34.	
		SANDEL, ed., "Industrial Aspects of Pharmaceuticals", Swedish Pharmaceutical Press, (1993), pages 93-104 and 191-211.	
		LEUNG et al., in "Controlled Drug Delivery: Fundamentals and Applications" (Drugs and the Pharmaceutical Sciences; vol 29), 2nd Ed., Robinson and Lee, eds., Dekker (1987), chapter 10, pp. 433-480.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.